Segmental and regional differences in neuronal expression of the leech Hox genes Lox1 and Lox2 during embryogenesis.

Using double immunofluorescence experiments, we described the expression of the leech Hox genes, Lox1 and Lox2 by central neurons that stained for either serotonin or the leech-specific neuronal marker, Laz1-1. The goal is to determine whether the segmental boundaries of Lox1 and Lox2 expression in identified neurons coincide with segmental and regional differences in the differentiation of these cells. A number of neurons described here have been previously identified. The anteromedial serotonergic neurons are restricted to rostral ganglion 1 (R1) to midbody ganglion 3 (M3), but only express Lox1 in M2 and M3. The posteromedial serotonergic neurons which are situated in all segments as bilateral pairs early in development, but later become unpaired starting at M3, expressed Lox1 only in M2 and M3, and Lox2 in M8 to M21, in all paired and unpaired stages. The Retzius neurons, which stain for serotonin, express Lox2 in M7 to M21 where they exhibit different morphologies from their segmental homologs of the sex ganglia in M5 and M6. The Laz1-1 immunoreactive (Laz1-1+) heart accessory-like neurons express Lox1 in M4 and Lox2 in M7 to M17, but not in their segmental homologs of the heart accessory (HA) neurons located exclusively in M5 and M6. Also, Laz1-1+ neurons, which we named Lz3 expressed Lox1 in M4 to M8 where they are unpaired, but express Lox2 in M9 to M16 where they are bilaterally paired. Other Laz1-1 cells show more restricted and isolated Lox1 and Lox2 expression patterns. These results suggest a role of Lox1 and/or Lox2 in defining the anteroposterior boundaries of segmentally iterated neurons.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Segmental and regional differences in neuronal expression of the leech Hox genes Lox1 and Lox2 during embryogenesis.

Explore how this research connects to clinical practice

More peer-reviewed studies in Drug Development.

• Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
• Medicinal Leech Genome Assembly — Anticoagulant Gene Catalog — Kvist et al. (2020)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• Hirudotherapy in Medicine and Dentistry — Jha K et al. (2015)
• Medicinal leech therapy (hirudotherapy): a brief overview — Singh A (2010)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• Investigation of oxidant-antioxidant status in patients treated with hirudotherapy: an experimental study — Sarikan I, Savas H (2024)
• Leech therapeutic applications — Abdualkader A et al. (2013)
• Non-Occlusive Mesenteric Ischemia Due to Hirudotherapy: A Case Report — Akalın Ç, Ekmen N (2020)
• Leech therapy: a history — Hyson J (2005)

Browse all ASH-analysed research →